BILL ANALYSIS                                                                                                                                                                                                    



                                                                  AB 2145
                                                                  Page  1


          ASSEMBLY THIRD READING
          AB 2145 (Ammiano)
          As Amended May 28, 2010
          Majority vote 

           JUDICIARY           9-0         APPROPRIATIONS      17-0        
           
           ----------------------------------------------------------------- 
          |Ayes:|Feuer, Tran, Brownley,    |Ayes:|Fuentes, Conway, Ammiano, |
          |     |Hill, Hagman, Huffman,    |     |Bradford, Charles         |
          |     |Skinner, Monning, Nava    |     |Calderon, Coto, Davis,    |
          |     |                          |     |Monning, Ruskin, Harkey,  |
          |     |                          |     |Miller, Nielsen, Norby,   |
          |     |                          |     |Skinner, Solorio,         |
          |     |                          |     |Torlakson, Torrico        |
          |     |                          |     |                          |
          |-----+--------------------------+-----+--------------------------|
          |     |                          |     |                          |
           ----------------------------------------------------------------- 
           SUMMARY  :  Seeks to expand parameters of the current pilot  
          program authorizing opioid antagonist (Naloxone) treatment of  
          drug overdose with limited immunity from liability.   
          Specifically,  this bill  :   

          1)Provides that a person who is not otherwise licensed to  
            administer an opioid antidote may administer an opioid  
            antidote in an emergency without fee, if the person believes  
            in good faith that the other person is experiencing a drug  
            overdose, and has received specified training through a  
            training program operated or registered by the local health  
            jurisdiction.  Further provides that the person shall not, as  
            a result of his or her acts or omissions, be liable for any  
            violation of any professional licensing statute, or subject to  
            any criminal prosecution related to the unauthorized practice  
            of medicine or possession of an opioid antidote.

          2)Deletes the provision that currently restricts application of  
            the Naloxone treatment pilot program to only seven authorized  
            counties, thereby expanding application of these provisions  
            statewide.

          3)Deletes the sunset date provision that would repeal authority  
            for the Naloxone treatment pilot program on January 1, 2011,  
            thereby extending these provisions indefinitely.








                                                                  AB 2145
                                                                  Page  2



          4)Deletes the requirement that each local health jurisdiction  
            that operates or registers an opioid overdose prevention and  
            treatment training program must report specified data by  
            January 1, 2010 to the Senate and Assembly Judiciary  
            Committees.

           FISCAL EFFECT  :  According to the Assembly Appropriations  
          Committee, no direct fiscal impact is created by this bill. 

           COMMENTS  :  This bill, co-sponsored by Harm Reduction California  
          and the Los Angeles Overdose Prevention Task Force, seeks to  
          expand parameters of the current pilot project that grants  
          limited immunity from civil and criminal penalties to licensed  
          health care providers in seven counties who are authorized to  
          prescribe and distribute opioid antagonists for emergency  
          treatment of drug overdose.  First, the bill would expand  
          limited immunity from civil and criminal liability to lay  
          persons who administer an opioid antagonist in an emergency, if  
          that lay person has received appropriate training through a  
          program operated or registered by the local health jurisdiction.  
           In practice, these persons are most likely to be friends or  
          acquaintances of the person using opioid drugs, present when an  
          overdose begins and thus in the best position to intervene and  
          administer the opioid antagonist at a point when it will have  
          its greatest lifesaving effect.  This bill would also expand the  
          pilot provisions statewide, while simultaneously deleting the  
          2011 sunset date, thereby extending these provisions  
          indefinitely.
           
           Opioid overdoses are characterized by central nervous system and  
          respiratory depression, leading to coma and death.  Naloxone,  
          like other opioid antagonists, has the ability to counteract  
          depression of the central nervous and respiratory system caused  
          by an opioid overdose.  Naloxone is administered by injection  
          into vein or muscle, with intravenous injection providing for  
          the fastest action.  Once injected, naloxone takes effect after  
          around two minutes, with effects lasting around 45 minutes,  
          potentially saving the person's life.  

          According to the Harm Reduction Coalition, overdose prevention  
          programs that dispense naloxone (often referred to as "naloxone  
          prescription programs", or NPPs) have been operating legally in  
          California for ten years, with different levels of support from  








                                                                  AB 2145
                                                                  Page  3


          city and county public health departments and community-based  
          organizations.  

          Proponents of this bill contend, very simply, that naloxone  
          prescription programs save lives, and that available data from  
          San Francisco and Los Angeles pilot programs demonstrate that  
          these programs are actively being used to produce safe and  
          effective health outcomes.  With respect to liability concerns,  
          the Judiciary Committee has not been made aware of any suits or  
          prosecutions as a result of the current distribution of opioid  
          antagonists.

          Proponents of this bill contend that accidental drug overdose is  
          a prevalent problem across the state, and that expansion of the  
          pilot program would help to address unmet needs in many counties  
          that currently do not enjoy the protections provided by the SB  
          767 pilot project.  According to the most recent report by  
          California Alcohol and Drug Programs, the counties with the  
          highest number of overdose deaths in 2006 were Kern, Orange,  
          Riverside, Sacramento, San Bernardino, San Diego, Santa Clara,  
          Alameda, Fresno, San Francisco, and Los Angeles.  The author  
          notes that only the latter four counties are authorized as sites  
          for pilot programs in SB 767, and asserts that there are a  
          number of counties that already have NPPs that merit protection,  
          as well as many high-need counties yet to implement programs  
          that would stand to benefit from statewide expansion proposed by  
          this bill.

          Supporters contend that because naloxone cannot be  
          self-administered by the person experiencing the overdose, it is  
          recommendable to extend protection from liability to third  
          parties who are trained to administer naloxone, or else they  
          will simply avoid employing naloxone in an emergency even when  
          it is available.  The author explains:

               Opioid overdose is characterized by unconsciousness  
               caused by failure of the respiratory system.  
               Therefore, if the person prescribed naloxone is the  
               one who is at-risk, he will not be able to use it on  
               himself when actually needed.  A companion trained in  
               naloxone administration must be present to administer  
               the life-saving drug. Friends, family members, workers  
               in homeless shelters, residential hotels, and drug  
               treatment programs are often first responders in an  








                                                                  AB 2145
                                                                  Page  4


               overdose crisis, but may be fearful to carry a  
               naloxone prescription because of the lack of 3rd party  
               protection. A trained, informed Good Samaritan  
               deserves to keep naloxone in the first aid kit or  
               medicine cabinet without needless concern.
           
          Supporters report that county health workers who operate or who  
          desire to operate a NPP report having difficulty finding health  
          care providers who are comfortable writing prescriptions for a  
          medication that will, by necessity, be administered by a third  
          party, without reasonable liability protection.  Furthermore,  
          supporters assert that even so-called "frontline workers" who  
          have taken overdose prevention trainings, and who often are in  
          close contact with drug users at sites like homeless shelters  
          and drug treatment facilities, nevertheless are reluctant to  
          keep the naloxone close at hand for emergency response, without  
          any legal protection for a third party who administrates  
          naloxone.


           Analysis Prepared by :   Anthony Lew / JUD. / (916) 319-2334 


                                                                FN: 0004660